Sector
PharmaceuticalsOpen
₹2,107.7Prev. Close
₹2,105.4Turnover(Lac.)
₹23,206.27Day's High
₹2,115.9Day's Low
₹2,053.252 Week's High
₹2,402.952 Week's Low
₹1,493.3Book Value
₹510Face Value
₹2Mkt Cap (₹ Cr.)
94,376.56P/E
30.76EPS
68.52Divi. Yield
0.386 May 2024
12:00 AM
Dividend
Dividend Amount: 8
Record Date: 16 Jul, 2024
31 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
9 Jul 2024
12:00 AM
AGM
Announcement Date: 09 Jul, 2024
The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.
The acquisition enhances Lupin’s portfolio of branded medicines and is aimed at furthering the company’s commitment to providing affordable and sustainable healthcare solutions.
Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.
Here are some of the stocks that may see significant price movement today: IREDA, Gensol Engineering, Tata Power, etc.
The inspection covered the period from January 27 until January 31, 2025, and was used to assess cGMP and other regulatory requirements at the facility
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 91.22 | 91 | 90.9 | 90.79 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 20,511.87 | 18,320.86 | 18,059.29 | 18,474.78 |
Net Worth | 20,603.09 | 18,411.86 | 18,150.19 | 18,565.57 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 11,771.67 | 11,055.93 | 11,025.66 | 10,080.58 |
yoy growth (%) | 6.47 | 0.27 | 9.37 | -20.16 |
Raw materials | -4,467.26 | -4,182.31 | -4,207.27 | -3,474.35 |
As % of sales | 37.94 | 37.82 | 38.15 | 34.46 |
Employee costs | -1,918.16 | -1,695.86 | -1,703.22 | -1,441.64 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -161.53 | 1,629.7 | 1,811.46 | 1,793.93 |
Depreciation | -514.19 | -502.83 | -518.75 | -389.81 |
Tax paid | -27.17 | -371.08 | -324.7 | -449.27 |
Working capital | -135.75 | -894.67 | -203.16 | 1,003.92 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.47 | 0.27 | 9.37 | -20.16 |
Op profit growth | -89.76 | 7.15 | -8.54 | -53.5 |
EBIT growth | -105.27 | -10.39 | 2.01 | -56.58 |
Net profit growth | -114.99 | 72.99 | -45.89 | -57.19 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | 15,142.8 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | 15,142.8 |
Other Operating Income | 354.48 | 371.68 | 212.69 | 235.97 | 231.96 |
Other Income | 120.17 | 73.36 | 142.05 | 137.62 | 617.8 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,805.5 | 137.46 | 4,33,031.98 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,108 | 78.27 | 1,62,251.74 | 594 | 0.49 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,541.5 | 26.74 | 1,24,457.39 | 1,438.15 | 0.84 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,322.7 | 61.63 | 1,12,419.76 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,556.9 | 54.56 | 1,05,504.58 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
M D Gupta
Managing Director
Nilesh Deshbandhu Gupta.
Director & Chief Executive Off
Vinita Gupta
Company Sec. & Compli. Officer
R V Satam
Independent Director
Jean-Luc Belingard
Executive Director & CFO
Ramesh Swaminathan
Independent Director
Mark D McDade
Independent Director
K B S Anand
Independent Director
Punita Kumar Sinha
Independent Director
Jeffrey Kindler
Independent Director
Alfonso Zulueta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lupin Ltd
Summary
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited. In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the y
Read More
What is the Lupin Ltd share price today?
The Lupin Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2067.1 today.
What is the Market Cap of Lupin Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd is ₹94376.56 Cr. as of 29 Apr ‘25
What is the PE and PB ratio of Lupin Ltd?
The PE and PB ratios of Lupin Ltd is 30.76 and 4.38 as of 29 Apr ‘25
What is the 52 Week High and Low of Lupin Ltd?
The 52-week high/low is the highest and lowest price at which a Lupin Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lupin Ltd is ₹1493.3 and ₹2402.9 as of 29 Apr ‘25
What is the CAGR of Lupin Ltd?
Lupin Ltd's CAGR for 5 Years at 19.33%, 3 Years at 40.54%, 1 Year at 26.24%, 6 Month at -6.30%, 3 Month at -0.05% and 1 Month at 5.71%.
What is the shareholding pattern of Lupin Ltd?
The shareholding pattern of Lupin Ltd is as follows:
Promoters - 46.92 %
Institutions - 46.88 %
Public - 6.20 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
